Medical Ethics Committees and Institutional Review Boards – Research Oversight

Definition and Core Concept

This article defines Institutional Review Boards (IRBs) —also called Research Ethics Committees (RECs) or Independent Ethics Committees (IECs)—as independent bodies established to review, approve, and monitor research involving human participants. Their primary purpose is to protect the rights, welfare, and dignity of individuals enrolled in research studies. Medical ethics committees (broader scope) also advise on clinical ethics dilemmas (e.g., informed consent, end-of-life decisions, resource allocation) in healthcare institutions. Core features: (1) protocol review (assessing scientific merit, risks, benefits, informed consent process), (2) continuing review (annual or more frequent monitoring of ongoing studies), (3) expedited vs full board review (tiered review based on risk level), (4) reporting of unexpected events (adverse events, protocol deviations), (5) committee composition (scientific members, non-scientific members, community representatives, at least one member not affiliated with the institution). The article addresses: objectives of IRBs/ethics committees; key concepts including informed consent, minimal risk, and vulnerable populations; core mechanisms such as risk-benefit assessment, consent form review, and post-approval monitoring; international comparisons and debated issues (single vs multiple IRB review, expedited review criteria, community engagement); summary and emerging trends (centralised IRBs, digital consent, patient and public involvement); and a Q&A section.

1. Specific Aims of This Article

This article describes IRBs and medical ethics committees without endorsing specific procedures. Objectives commonly cited: ensuring voluntary informed consent, minimising risks, balancing risks against potential benefits, selecting participants equitably, and providing independent oversight. The article notes that IRB systems vary by country, but most follow principles from the Declaration of Helsinki (1964, multiple revisions) and the Belmont Report (1979).

2. Foundational Conceptual Explanations

Key terminology:

• Informed consent (research context): Process providing potential participants with information about study purpose, procedures, risks, benefits, alternatives, confidentiality, voluntary participation, and right to withdraw without penalty.
• Minimal risk: Probability and magnitude of harm or discomfort not greater than those encountered in daily life or routine physical/psychological examinations.
• Vulnerable populations: Groups requiring additional protections: children, pregnant individuals, prisoners, individuals with cognitive impairment, economically disadvantaged, educationally disadvantaged.
• Expedited review (not full board): For research involving no more than minimal risk, reviewed by one IRB member or a small subgroup rather than full committee.
• Continuing review (annual renewal): IRB re-evaluation of ongoing studies at least once per year (more often for higher-risk studies).

Committee composition (US federal regulations – Common Rule):

• At least five members with varying backgrounds.
• At least one scientifically knowledgeable member.
• At least one member whose primary concerns are non-scientific (e.g., lawyer, ethicist, clergy).
• At least one member not affiliated with the institution (community member).
• Members of both sexes (if possible).

3. Core Mechanisms and In-Depth Elaboration

Risk-benefit assessment factors:

• Magnitude and probability of physical, psychological, social, and economic harms.
• Direct benefits to participants (e.g., access to experimental treatment).
• Social benefits (e.g., generalisable knowledge).
• Whether risks are minimised (sound study design, qualified personnel, adequate monitoring).

Informed consent document requirements (Common Rule §46.116):

• Statement that study involves research.
• Purpose, duration, procedures.
• Reasonably foreseeable risks.
• Potential benefits.
• Alternative procedures or treatments.
• Confidentiality protections.
• Compensation and medical treatment for injury (if applicable).
• Contact information for questions.
• Voluntary participation statement.

Levels of review:

• Exempt (not requiring full IRB review): Educational practices, surveys (non-identifiable), existing data (publicly available), taste/food studies.
• Expedited (minimal risk): Blood draws (limited volume), prospective specimen collection (non-invasive), voice recordings, moderate exercise, behavioural interventions.
• Full board review (greater than minimal risk): Drug trials, device studies, invasive procedures, vulnerable populations.

Single IRB review (multisite studies): US NIH policy (2016) requires single IRB for domestic multisite studies (exceptions). Reduces duplication, improves efficiency. Reliance agreements between institutions.

Effectiveness evidence:

• Inter-rater reliability studies: Moderate agreement among IRBs for same protocol (kappa 0.4-0.6). Variation in interpretations of risk categories.
• Single IRB implementation reduces time to approval (by 2-4 weeks) and administrative burden (30-50% reduction) for multisite trials.

4. International Comparisons and Debated Issues

IRB systems across regions:

Debated issues:

1. Expedited review criteria expansion: Some argue that many low-risk studies (e.g., chart review, surveys) should be exempt or expedited without delaying research. Others worry about erosion of protections.
2. Community engagement in IRB (patient and public involvement): Community members on IRBs bring perspective but may lack technical training. Training and support help.
3. Digital informed consent (electronic consent, eConsent, remote consent): Can improve participant understanding (interactive modules, quizzes) but raises questions about documentation, privacy, and signature validity.

5. Summary and Future Trajectories

Summary: IRBs/RECs review research protocols to protect human participants. Committees must be multidisciplinary (scientific, non-scientific, community members). Review levels: exempt, expedited, full board. Informed consent requires disclosure, understanding, voluntariness. Single IRB for multisite studies improves efficiency but implementation varies.

Emerging trends:

• Centralised IRBs (commercial or academic independent IRBs): Used for industry-sponsored and multisite studies; faster turnaround times.
• Digital consent (eConsent) with embedded comprehension checks and electronic signatures.
• Broad consent for storage of biospecimens and data (enables future secondary research).
• Patient and public involvement (PPI) in research ethics committees (UK HRA, PCORI).

6. Question-and-Answer Session

Q1: Does every research study require IRB approval?
A: In most jurisdictions, any research involving living human participants, their data, or their biospecimens requires review by an IRB/REC (or determination of exemption). Quality improvement activities not intended to produce generalisable knowledge may not require review; boundaries can be unclear.

Q2: How long does IRB review typically take?
A: Exempt or expedited review: 1-4 weeks. Full board review (convened meeting): 4-8 weeks from submission. Resubmissions for revisions: 2-4 weeks. Single IRB for multisite studies may add 2-6 weeks for reliance agreements.

Q3: Can a researcher serve on their own institution’s IRB?
A: Yes, but they must recuse themselves from reviewing their own studies. IRBs should include at least one member who is not affiliated with the institution (community member) to reduce institutional bias.

Q4: What happens if an IRB disapproves a study?
A: The researcher may revise the protocol and resubmit, appeal the decision (if institutional policy permits), or seek review by a different IRB (if allowed). Disapproval typically requires documented reasons (insufficient risk minimisation, inadequate consent, vulnerable population concerns).

https://www.hhs.gov/ohrp/ (Office for Human Research Protections)
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-boards
https://www.ema.europa.eu/en/human-regulatory/research-development/ethics-committees
https://www.hra.nhs.uk